eli lilly glp-1 receptor agonist medications As Use Expands, Long-Term Safety Questions Remain Under Watch New GLP-1 Guidelines for Type

Larger manufacturers must stop May 22

doi: 10.2337/dci17-0057 224 HeineRJVan GaalLFJohnsDMihmMJWidelMHBrodowsRGet al

all require a prescription, licensing-appropriate use, and ongoing clinical oversight

These rogue outfits should be avoided

Not all patients respond equally to GLP-1 agonist therapy, and identifying optimal candidates requires considering multiple factors, including baseline weight, comorbidities, and individual tolerance profiles

Data were obtained from Summaries of Product Characteristics T2DM type 2 diabetes mellitus, OB obesity, OW overweight, SC subcutaneous, OS oral use, GLP-1 glucagon-like peptide 1, GIP gastric inhibitory polypeptide, DPP4 dipeptidyl peptidase 4, NEP enzyme neutral endopeptidase GLP-1 RAs mimic the action of the endogenous incretin hormone GLP-1 by activating GLP-1 receptors in pancreatic -cells